Life sciences venture capital firm Sofinnova Partners has sold its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1bn.
Life sciences venture capital firm Sofinnova Partners has sold its portfolio company Corvidia Therapeutics to Novo Nordisk for $2.1bn.